Compare Cassava Sciences Inc (FLNA) vs Macy's Inc (M) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Macy's (M) trades at $24.04, up 3.55% today, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.29, while recent news highlights strategic initiatives including AI integration and leadership appointments. Cash flow trends improved in 2025 with net cash flow of $273 million, though revenue declined slightly to $23.01 billion.

Outlook remains cautiously optimistic with a consensus price target of $24.83 offering modest upside. Key opportunities include operational efficiency gains and luxury segment growth, while risks involve competitive retail pressures and macroeconomic sensitivity. Institutional interest is growing with Berkshire Hathaway's recent 3 million share purchase (Barron's, June 22, 2026).